These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2891030)

  • 1. Serotonergic mechanisms of hallucinogenic drug effects.
    Heym J; Jacobs BL
    Monogr Neural Sci; 1987; 13():55-81. PubMed ID: 2891030
    [No Abstract]   [Full Text] [Related]  

  • 2. Receptor pharmacology of MDMA and related hallucinogens.
    Teitler M; Leonhardt S; Appel NM; De Souza EB; Glennon RA
    Ann N Y Acad Sci; 1990; 600():626-38; discussion 638-9. PubMed ID: 1979215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors.
    Scheffel U; Lever JR; Stathis M; Ricaurte GA
    Neuropharmacology; 1992 Sep; 31(9):881-93. PubMed ID: 1359444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin receptors in the brain.
    Haigler HJ; Aghajanian GK
    Fed Proc; 1977 Jul; 36(8):2159-64. PubMed ID: 326580
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of drug discrimination procedures to characterize hallucinogenic drug actions.
    Appel JB; Cunningham KA
    Psychopharmacol Bull; 1986; 22(3):959-67. PubMed ID: 3797596
    [No Abstract]   [Full Text] [Related]  

  • 7. Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT2 receptor.
    McClue SJ; Brazell C; Stahl SM
    Biol Psychiatry; 1989 Jul; 26(3):297-302. PubMed ID: 2742945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemistry and pharmacology of hallucinogens, entactogens and stimulants.
    Kovar KA
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():69-72. PubMed ID: 9754836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
    Dimpfel W; Spüler M; Nichols DE
    Psychopharmacology (Berl); 1989; 98(3):297-303. PubMed ID: 2568652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.
    Sloviter RS; Drust EG; Damiano BP; Connor JD
    J Pharmacol Exp Ther; 1980 Aug; 214(2):231-8. PubMed ID: 6104720
    [No Abstract]   [Full Text] [Related]  

  • 11. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
    Oberlender R; Nichols DE
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered states: the clinical effects of Ecstasy.
    Cole JC; Sumnall HR
    Pharmacol Ther; 2003 Apr; 98(1):35-58. PubMed ID: 12667887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinogens and Drosophila: linking serotonin receptor activation to behavior.
    Nichols CD; Ronesi J; Pratt W; Sanders-Bush E
    Neuroscience; 2002; 115(3):979-84. PubMed ID: 12435434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemistry and neurotoxicity of substituted amphetamines.
    Wagner J; Peroutka SJ
    Neuropsychopharmacology; 1990 Jun; 3(3):219-20. PubMed ID: 1973040
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonergic neurotoxicity of methylenedioxyamphetamine and methylenedioxymetamphetamine.
    Monks TJ; Bai F; Miller RT; Lau SS
    Adv Exp Med Biol; 2001; 500():397-406. PubMed ID: 11764973
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.
    Nichols DE
    J Psychoactive Drugs; 1986; 18(4):305-13. PubMed ID: 2880944
    [No Abstract]   [Full Text] [Related]  

  • 18. The hallucinogens and the inhalants.
    Cohen S
    Psychiatr Clin North Am; 1984 Dec; 7(4):681-8. PubMed ID: 6097885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolealkylamine and phenalkylamine hallucinogens: a brief overview.
    Glennon RA; Rosecrans JA
    Neurosci Biobehav Rev; 1982; 6(4):489-97. PubMed ID: 6757811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.